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Alzheimer’s disease (AD) was first described by German 
psychiatrist and neuropathologist Alois Alzheimer in 1906 
and was named after him. It is the most common form of 
dementia and highly prevalent. AD is predicted to affect one 
in 85 people globally by 2050. Well-known examples in-
clude Ronald Reagan, former US President, and Charles K. 
Kao, recipient of the 2009 Nobel Prize in Physics. 
The neuropathology of AD is characterized by loss of 
neurons and synapses in cerebral cortex and certain subcor-
tical regions. Both amyloid plaques and neurofibrillary tan-
gles are clearly visible by microscopy in brains of those 
afflicted by AD. However, the cause for most Alzheimer’s 
cases remains essentially unknown, except for 1%–5% of 
cases where genetic differences have been identified. Sev-
eral competing hypotheses exist, trying to explain the cause 
of this disease, such as cholinergic hypothesis, amyloid hy-
pothesis, and Tau hypothesis.  
1  Mechanism of AD 
Currently, China’s population of old age has been increas-
ing. AD is most often diagnosed in people over 65 years of 
age. AD becomes a prominent issue in old people, drawing 
more attention to studies on its mechanism, imaging for 
diagnosis and treatment. In this article, we briefly review 
some progress made in this area by Chinese researchers. 
Because AD is the most common cause of progressive 
cognitive decline in the aged population and most often 
diagnosed in people over 65 years of age, what is the rela-
tionship between brain aging and AD has to be considered. 
A relevant review was provided by Chui et al. This review 
addresses specific issues including whether AD and brain 
aging should be conceptually lumped or split, to what  
extent AD and brain aging potentially share common mo-
lecular mechanisms, whether  amyloid (A) should be 
primarily considered as a marker of AD or simply that of 
brain aging, and what the definition of AD itself is. Moreo-
ver, an important common biochemical process shared by 
human aging and AD, carbonyl stress, has been discussed 
by Yin et al. They investigated the upstream molecular 
causes of AD, strategies based on this mechanism for treat-
ing AD, as well as for preventing aging, fatigue and 
sub-health. 
Amyloid hypothesis is prevalent for explaining the cause 
of AD. Based on this hypothesis, the deposition of Aβ is a 
crucial progression in the pathophysiology of AD. It is also 
considered to be a promising candidate for AD therapy by 
decreasing its formation and/or increasing its clearance. In 
Aβ production cascade, there are some important enzymes, 
one of which is Aβ precursor protein cleaving enzyme 1 
(BACE1). By the regulation of BACE1, decreasing Aβ 
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formation may be achieved. Therefore, Wang Tan and Sun 
XiuLian investigated the molecular regulation of BACE1 
and its function at the early onset of AD. It was demon-
strated that some of the pathological changes at the early 
onset of AD, such as ischemia, hypoxia, inflammation and 
stress, are considered to be BACE1-related. Besides, it was 
suggested that many BACE1- and Aβ-related cytokines in 
fluids may become potential biomarkers, which would pro-
vide ideas for early clinical diagnosis of AD. Likewise, in-
creasing its clearance is other potential way to treat AD. 
Although Aβ can be cleared through transportation to blood 
and cerebral spinal fluid pathway, most Aβ peptide is de-
graded to small molecules by a protease called Aβ degrad-
ing enzyme such as neprilysin (NEP). A review on the role 
of NEP in the pathogenesis of AD was provided by Yang 
HongQi and Xing Ying in 2012. It was suggested that NEP 
may behave as a potential drug target for AD therapy. 
Tau hypothesis is also considered to be a possible mo-
lecular mechanism underlying AD. Tau is the most abun-
dant microtubule-associated protein. The normal function of 
Tau is to promote microtubule assembly and stabilize mi-
crotubules. In AD, Tau is abnormally hyperphosphorylated 
and accumulated in the neuron to form neurofibrillary tan-
gles. Wang JianZhi’s group has systemically studied the 
mechanisms underlying Tau hyperphosphorylation and the 
effects of Tau phosphorylation on cell viability. It was pro-
posed that Tau hyperphosphorylation may play a dual role 
in leading the neurons to abort from an acute apoptosis and 
at the same time trigger chronic neurodegeneration. It is 
implied that appropriate interference of Tau hyperphos-
phorylation may be used as a promising strategy in rescuing 
cell apoptosis and arresting neurodegeneration in AD. Fur-
thermore, clinical trials indicated that some symptoms of 
AD patients can be alleviated by the supplementation of 
melatonin, which is an endogenously produced hormone in 
the brain and decreases in aged people and AD patients. The 
possible mechanism of melatonin function may be that it 
efficiently attenuates Tau hyperphosphorylation. 
Except for the aforementioned competing hypotheses, 
recently there have been others trying to explain AD. 
Among them, one hypothesis states that oxidative stress and 
dys-homeostasis of biometal (biology) metabolism may be 
important in the formation of AD pathology. The bio-metals 
of copper, zinc, iron, and manganese are examples that are 
essential for the normal functioning of the human body. 
Zhao BaoLu and Wan Li reviewed metal metabolic homeo-
stasis disruption and early initiation of mechanism for AD. 
It was shown that the overload of iron and copper might 
have close relationships with oxidative stress damage in the 
later phase of AD, while the deficiency of them might be 
relevant to the early initiation of AD. This may be useful for 
further research on the prevention and therapy of AD. 
There is also some latest development in studies of AD 
mechanism in China. Tong ZhiQian et al. performed an 
investigation and concluded that excess endogenous for-
maldehyde induces memory decline. Scavenging excess 
formaldehyde may be a novel therapy for AD. What is more, 
Su Tao et al. showed effective assay brain endogenous for-
maldehyde. In addition, the decrease of brain estrogen was 
considered to be closely involved in female AD patients. 
Less estrogen receptor β (ERβ) was detected in mitochon-
drial, nuclear, and cytosolic fractions in female AD brains. 
Further studies of ERβ in mice suggested that ERβ might 
play roles in regulating mitochondrial function and affect 
the function of neurons accordingly. 
2  Imaging for AD  
Some imaging techniques have been used as clinical and 
diagnostic tools for AD, and others are promising for AD 
studies. Here, we will briefly introduce them in terms of 
their imaging levels.  
As an important instrument in neuroscience research, 
two-photon fluorescence light microscopy invented by 
Denk et al. improved three-dimensional in vivo imaging of 
cells and tissues. However, two-photon microscopy provid-
ed commercially can hardly meet the need for the detection 
of neural signal at millisecond scale due to its low imaging 
rates. Proposed by Zeng ShaoQun’s group in China, fast 
random-access two-photon microscopy based on acousto- 
optic deflector has the potential to increase the observation 
speed while maintaining adequate signal-to-noise ratio. 
Jiang RunHua et al. from this group summarized the latest 
research progress. It was suggested that this technology may 
provide a new tool for neural activity observation and boost 
the development of brain science and it may be helpful for 
AD studies. 
Some advanced medical imaging techniques have been 
available as diagnostic tools, such as computed tomography, 
magnetic resonance imaging, single-photon emission com-
puted tomography, positron emission tomography, which 
can be synergistically used to confirm AD diagnosis. How-
ever, these diagnostic neuroimaging tools available in clin-
ics have demonstrated only regional structural and func-
tional changes instead of those in structural and functional 
networks in AD. 
Recent progress in multi-modal imaging techniques and 
human brain connectome methods has allowed us to explore 
alterations of structural and functional networks in AD. 
More details about these techniques can be obtained in a 
review on advances in AD with neuroimaging presented by 
He Yong. Using these approaches, many studies have dis-
covered AD-related network disruption, including connec-
tivity strength, network efficiency, modular structure and 
network hubs. These studies provide novel insight into AD 
notion of network disintegration and might lead to the dis-
covery of disease biomarkers for early diagnosis of AD. 
In neuroscience, studies have been conducted concerning 
the brain-wide complex neural network of mammals’ brains 
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in physiological and pathological states. However, due to 
technological limitations, conventional imaging tools can 
only be used to study the local circuits of higher animals or 
the small brain network of lower animals. In 2010, Li AnAn 
et al. presented the whole brain imaging methods, which are 
promising at the level of optical microscopy and used to 
study the brain-wide complex neural network of mammals’ 
brains. Furthermore, Li AnAn and Gong Hui reviewed re-
cent progress in the methods at the level of optical micros-
copy.  
3  Treatments for AD 
It is well known that no treatment is available for stopping 
or reversing the progression of AD. Current treatments are 
only helpful in attenuating the symptoms of AD. Based on 
the Aβ cascade hypothesis, the inhibition of Aβ production 
and aggregation as well as improvement of its clearance 
have been the main strategy for drug development. Howev-
er, a disturbing issue is that no effective approach is availa-
ble, although a large number of compounds have been in 
clinical trials. This issue probably can be explained by the 
following three reasons. Firstly, the Aβ hypothesis that Aβ 
is the key pathologic factor leading to AD progression 
might be questionable. Secondly, the loss of neural cells 
might be already too extensive, i.e., the poor clinical out-
come of AD treatment is due to late intervention. New di-
agnostic ways may help to identify individuals before sub- 
stantial neural damage has occurred to them. Treatments 
could then be attempted to stave off the onset of the disor-
ders or the progression of the disease. Thirdly, the failure to 
develop effective AD therapeutic agents in clinical trials 
could also be due to single-target or single-pathogenic 
pathway effect. The multi-target and multi-link treatment 
characteristics of traditional Chinese medicine have ad-
vantages over the single target treatment. The study of Li 
Lin and Zhang Lan showed that traditional Chinese medi-
cine formula (Shenwu capsule) and single herb extracts 
(tetrahydroxy-stilbene glucoside, cornel iridoid glycoside, 
epimedium flavone and icariin) could act on the complex 
pathogenesis of AD at multi-targets and multi-pathways, 
especially having both neuroprotective and neurotrophic/ 
regenerative effects, and protect mitochondria and synapses, 
thus having significant features and advantages for the 
treatment of AD. 
In brief, as the most common dementia in aged popula-
tion, the cause for most AD remains unknown, as well as 
the mechanism of neuronal degeneration in AD. No treat-
ment has been available for stopping or reversing the pro-
gression of AD until now. As China is stepping into ‘aged 
society’, AD becomes a prominent issue in old people, 
drawing increasing attention. The potential to answer ques-
tions on the cause and mechanisms of AD and to treat this 
devastating disease makes this time a critical one in AD 
research. As AD studies are flourishing in China, it is rea-
sonable to think that further breakthroughs will be achieved. 
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